{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:21:07Z","timestamp":1790011267554,"version":"4.0.1"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Reducing doses of antiretroviral drugs, including stavudine (d4T), may lower toxicity, while preserving efficacy. There are substantial concerns about renal and bone toxicities of tenofovir disoproxil fumarate (TDF).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Setting:<\/jats:title>\n            <jats:p>HIV-1\u2013infected treatment-naive adults in India, South Africa, and Uganda.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A phase-4, 96-week, randomized, double-blind, noninferiority trial compared d4T 20 mg twice daily and TDF, taken in combination with lamivudine (3TC) and efavirenz (EFV). The primary endpoint was the proportion of participants with HIV-1 RNA &lt;50 copies per milliliter at 48 weeks. Adverse events assessments included measures of bone density and body fat. The trial is registered on Clinicaltrials.gov (NCT02670772).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Between 2012 and 2014, 536 participants were recruited per arm. At week 96, trial completion rates were 75.7% with d4T\/3TC\/EFV (n = 406) and 82.1% with TDF\/3TC\/EFV (n = 440, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.011). Noncompletion was largely due to virological failure [6.2% (33) with d4T\/3TC\/EFV versus 5.4% (29) with TDF\/3TC\/EFV; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.60]. For the primary endpoint, d4T\/3TC\/EFV was noninferior to TDF\/3TC\/EFV (79.3%, 425\/536 versus 80.8% 433\/536; difference = \u22121.49%, 95% CI: \u22126.3 to 3.3; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). Drug-related adverse event discontinuations were higher with d4T (6.7%, 36), than TDF (1.1%, 6; <jats:italic toggle=\"yes\">P &lt;<\/jats:italic> 0.001). Lipodystrophy was more common with d4T (5.6%, 30) than TDF (0.2%, 1; <jats:italic toggle=\"yes\">P &lt;<\/jats:italic> 0.001). Creatinine clearance increased in both arms, by 18.1 mL\/min in the d4T arm and 14.2 mL\/min with TDF (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.03). Hip bone density measures, however, showed greater loss with TDF.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Low-dose d4T combined with 3TC\/EFV demonstrated noninferior virological efficacy compared with TDF\/3TC\/EFV, but mitochondrial toxicity remained high. Little renal toxicity occurred in either arm. Implications of bone mineral density changes with TDF warrant investigation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/qai.0000000000001908","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T22:53:37Z","timestamp":1542149617000},"page":"224-233","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial"],"prefix":"10.1097","volume":"80","author":[{"given":"Willem Daniel Francois","family":"Venter","sequence":"first","affiliation":[{"name":"Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kambugu","sequence":"additional","affiliation":[{"name":"Infectious Diseases, College of Health Sciences at Makerere University, Kampala, Uganda;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew F.","family":"Chersich","sequence":"additional","affiliation":[{"name":"Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Becker","sequence":"additional","affiliation":[{"name":"Independent Consultant, Yountville, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hill","sequence":"additional","affiliation":[{"name":"Pharmacology Department, University of Liverpool, Liverpool, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Arulappan","sequence":"additional","affiliation":[{"name":"Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Moorhouse","sequence":"additional","affiliation":[{"name":"Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Majam","sequence":"additional","affiliation":[{"name":"Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godspower","family":"Akpomiemie","sequence":"additional","affiliation":[{"name":"Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simiso","family":"Sokhela","sequence":"additional","affiliation":[{"name":"Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvamuthu","family":"Poongulali","sequence":"additional","affiliation":[{"name":"Chennai Antiviral Research and Treatment Clinical Research Site, YRGCARE Medical Centre, Voluntary Health Services, Chennai, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Charlotte Maxeke Johannesburg Academic Hospital and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Duncombe","sequence":"additional","affiliation":[{"name":"HIV, Bill and Melinda Gates Foundation, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H. Brown","family":"Ripin","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alinda","family":"Vos","sequence":"additional","affiliation":[{"name":"Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa;"},{"name":"Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagalingeswaran","family":"Kumarasamy","sequence":"additional","affiliation":[{"name":"Chennai Antiviral Research and Treatment Clinical Research Site, YRGCARE Medical Centre, Voluntary Health Services, Chennai, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 1","key":"R3-20230926","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1097\/01.qai.0000137004.63376.27","article-title":"Mitochondrial dysfunction: patient monitoring and toxicity management","volume":"37","author":"McComsey","year":"2004","journal-title":"J Acquir Immune Defic Syndr."},{"key":"R4-20230926","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1086\/521150","article-title":"Adverse effects of highly active antiretroviral therapy in developing countries","volume":"45","author":"Subbaraman","year":"2007","journal-title":"Clin Infect Dis."},{"key":"R7-20230926","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/tmi.12008","article-title":"Dose reduction of antiretrovirals: a feasible and testable approach to expand HIV treatment in developing countries","volume":"18","author":"Vento","year":"2013","journal-title":"Trop Med Int Health."},{"key":"R8-20230926","first-page":"85","article-title":"Dose optimisation: a strategy to improve tolerability and lower antiretroviral drug prices in low and middle income countries","volume":"4","author":"Hill","year":"2010","journal-title":"Open Infect Dis J."},{"key":"R9-20230926","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1517\/14656566.8.5.679","article-title":"Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment","volume":"8","author":"Hill","year":"2007","journal-title":"Expert Opin Pharmacother."},{"key":"R10-20230926","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1310\/ED57-EU48-RK6A-E5U0","article-title":"Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity","volume":"6","author":"Sanchez-Conde","year":"2005","journal-title":"HIV Clin Trials."},{"key":"R11-20230926","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/135965350701200301","article-title":"The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients","volume":"12","author":"Milinkovic","year":"2007","journal-title":"Antivir Ther."},{"key":"R12-20230926","first-page":"CD007497","article-title":"Low dose versus high dose stavudine for treating people with HIV infection","volume":"1","author":"Magula","year":"2015","journal-title":"Cochrane Database Syst Rev."},{"key":"R17-20230926","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2478\/abm-2010-0068","article-title":"d4T: keep it or abandon it?","volume":"4","author":"Hill","year":"2010","journal-title":"Asian Biomed."},{"key":"R18-20230926","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1086\/529384","article-title":"Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study","volume":"46","author":"McComsey","year":"2008","journal-title":"Clin Infect Dis."},{"key":"R19-20230926","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hiv.12074","article-title":"A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients","volume":"15","author":"Menezes","year":"2014","journal-title":"HIV Med."},{"key":"R20-20230926","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA."},{"key":"R21-20230926","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/COH.0000000000000248","article-title":"Tenofovir and bone health","volume":"11","author":"Grant","year":"2016","journal-title":"Curr Opin HIV AIDS."},{"key":"R22-20230926","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/15284336.2016.1243363","article-title":"Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection","volume":"17","author":"Bedimo","year":"2016","journal-title":"HIV Clin Trials."},{"key":"R24-20230926","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/QAD.0b013e328340fdf8","article-title":"Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis","volume":"25","author":"Bendavid","year":"2011","journal-title":"AIDS."},{"key":"R25-20230926","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1086\/649884","article-title":"Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India","volume":"50","author":"Bender","year":"2010","journal-title":"Clin Infect Dis."},{"key":"R26-20230926","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/QAI.0b013e31817ae5ef","article-title":"Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa","volume":"48","author":"Rosen","year":"2008","journal-title":"J Acquir Immune Defic Syndr."},{"key":"R30-20230926","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4102\/sajhivmed.v14i1.100","article-title":"Overview of HIV-related lipodystrophy","volume":"14","author":"Rossouw","year":"2013","journal-title":"South Afr J HIV Med."},{"key":"R31-20230926","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1177\/135965350601100610","article-title":"HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1\/HAART-associated lipodystrophy","volume":"11","author":"Giralt","year":"2006","journal-title":"Antivir Ther."},{"key":"R32-20230926","first-page":"795","article-title":"Symptomatic hyperlactataemia in adults on antiretroviral therapy: a single-centre experience","volume":"98","author":"Fabian","year":"2008","journal-title":"S Afr Med J."},{"key":"R33-20230926","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"R34-20230926","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet."},{"key":"R35-20230926","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1016\/S2352-3018(16)00024-2","article-title":"Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial","volume":"3","author":"Gallant","year":"2016","journal-title":"Lancet HIV."},{"key":"R36-20230926","first-page":"184","article-title":"Is tenofovir alafenamide safer than tenofovir disoproxil fumarate for the kidneys?","volume":"18","author":"Aloy","year":"2016","journal-title":"AIDS Rev."},{"key":"R37-20230926","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7448\/IAS.20.01\/21317","article-title":"Changes in estimated glomerular filtration rate over time in South African HIV-1-infected patients receiving tenofovir: a retrospective cohort study","volume":"20","author":"De Waal","year":"2017","journal-title":"J Int AIDS Soc."},{"key":"R38-20230926","doi-asserted-by":"crossref","first-page":"e0166982","DOI":"10.1371\/journal.pone.0166982","article-title":"Real-world assessment of renal and bone safety among patients with HIV infection exposed to tenofovir disoproxil fumarate-containing single-tablet regimens","volume":"11","author":"Nkhoma","year":"2016","journal-title":"PLoS One."},{"key":"R39-20230926","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/QAD.0b013e328328f789","article-title":"Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients","volume":"23","author":"Duvivier","year":"2009","journal-title":"AIDS."},{"key":"R40-20230926","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/infdis\/jir188","article-title":"Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202","volume":"203","author":"McComsey","year":"2011","journal-title":"J Infect Dis."},{"key":"R41-20230926","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/656417","article-title":"Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study","volume":"51","author":"Stellbrink","year":"2010","journal-title":"Clin Infect Dis."},{"key":"R42-20230926","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1179\/1945577115Y.0000000004","article-title":"Comparative effectiveness of tenofovir in treatment-naive HIV-infected patients: systematic review and meta-analysis","volume":"16","author":"Hemkens","year":"2015","journal-title":"HIV Clin Trials."},{"key":"R43-20230926","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12981-016-0121-z","article-title":"Cases of antiretroviral-associated gynaecomastia reported to the National HIV and Tuberculosis Health Care Worker Hotline in South Africa","volume":"13","author":"Njuguna","year":"2016","journal-title":"AIDS Res Ther."},{"key":"R44-20230926","doi-asserted-by":"crossref","first-page":"e2844","DOI":"10.1097\/MD.0000000000002844","article-title":"Risk factors for incident diabetes in a cohort taking first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy","volume":"95","author":"Karamchand","year":"2016","journal-title":"Medicine (Baltimore)."},{"key":"R45-20230926","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1371\/journal.pmed.0010019","article-title":"Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1","volume":"1","author":"van Leth","year":"2004","journal-title":"PLoS Med."},{"key":"R46-20230926","first-page":"341","article-title":"The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism","volume":"19","author":"Alonso-Villaverde","year":"2005","journal-title":"AIDS."},{"key":"R47-20230926","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/15284336.2015.1112480","article-title":"Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia","volume":"17","author":"Thamrongwonglert","year":"2016","journal-title":"HIV Clin Trials."},{"key":"R48-20230926","doi-asserted-by":"crossref","first-page":"e0151911","DOI":"10.1371\/journal.pone.0151911","article-title":"Anti-retroviral therapy increases the prevalence of dyslipidemia in South African HIV-infected patients","volume":"11","author":"Dave","year":"2016","journal-title":"PLoS One."},{"key":"R49-20230926","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1080\/17512433.2016.1221760","article-title":"Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen","volume":"9","author":"Mouton","year":"2016","journal-title":"Expert Rev Clin Pharmacol."},{"key":"R51-20230926","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fendo.2015.00024","article-title":"Ethnic differences in bone health","volume":"6","author":"Zengin","year":"2015","journal-title":"Front Endocrinol (Lausanne)."},{"key":"R52-20230926","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4102\/sajhivmed.v13i1.155","article-title":"Why it's time to say goodbye to stavudine \u2026 everywhere: debate","volume":"13","author":"Andrieux-Meyer","year":"2012","journal-title":"South Afr J HIV Med."},{"key":"R53-20230926","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1473-3099(15)70060-5","article-title":"Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study","volume":"15","author":"Group","year":"2015","journal-title":"Lancet Infect Dis."}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00126334-201902010-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T21:58:07Z","timestamp":1695765487000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-201902010-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0000000000001908","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2,1]]}}}